

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>YAU YI CHING</u> (Last) (First) (Middle) C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET (Street) PALO ALTO CA 94301 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>BridgeBio Pharma, Inc. [ BBIO ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Accounting Officer		
			3. Date of Earliest Transaction (Month/Day/Year) 06/03/2020			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year)					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$28.86	06/03/2020		A		45,931		(1)	06/02/2030	Common Stock	45,931	\$0.00	45,931	D	
Restricted Stock Units	(2)	06/03/2020		A		6,383		(3)	(3)	Common Stock	6,383	\$0.00	6,383	D	

**Explanation of Responses:**

- The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date.
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date.

**Remarks:**

/s/ Tara Condon, Attorney-in-Fact      06/05/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.